Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)

NCT05068232 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT05068232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05068232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES)
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Recruiting
Start date
August 19, 2022
Completion date
October 1, 2027
Enrollment
49 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

extensive-stage small-cell lung cancer, lung cancer, small-cell lung cancer